Stocks

First patient dosed in DENALI Part 2a clinical trial of azenosertib in patients with Cyclin E1+ PROC Topline data from DENALI Part 2 anticipated by year end 2026 with the potential to support an accelerated approval, subject to FDA feedback $332.5 million cash, cash …

Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignancies Four oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies SAN CARLOS, Calif., May 14, 2025--(BUSINESS WIRE)--BeiGene, Ltd. …

Dividend Increases 3.3% to $1.26 Per Share - the 18th Consecutive Quarterly Increase Securities Repurchase Authorization Increases by Additional $250 Million BLOOMFIELD HILLS, Mich., May 14, 2025 /PRNewswire/ -- Penske Automotive Group, Inc. (NYSE: PAG), a diversified international transportation services company and one of …

Diagnostics company Guardant Health (NASDAQ:GH) announced better-than-expected revenue in Q1 CY2025, with sales up 20.8% year on year to $203.5 million. The company’s full-year revenue guidance of $885 million at the midpoint came in 3.2% above analysts’ estimates. Its non-GAAP loss of $0.49 per …

Chip stocks rallied on Wednesday after a wave of artificial intelligence (AI)–related announcements tied to Saudi Arabia. Patrick Moorhead, founder, CEO, and chief analyst at Moor Insights & Strategy, joins Market Domination to explain what's real and what's speculative in deals from Nvidia (NVDA), …

Tesla (TSLA) stock closed higher on Wednesday on reports that the company's board is once again exploring how to compensate CEO Elon Musk. Per the Financial Times, Tesla's board has formed a special committee to explore a new pay package for Musk, with stock …

Freight transportation intermediary C.H. Robinson (NASDAQ:CHRW) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 8.3% year on year to $4.05 billion. Its non-GAAP profit of $1.17 per share was 11.4% above analysts’ consensus estimates. Is now the time to buy CHRW? …